Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory biomarker involved in atherosclerosis and cardiovascular disease (CVD). Iron stores may modify Lp-PLA2 as higher activity levels wereobserved in patients with primary iron overload (IO).Aim: to evaluate the changes of Lp-PLA2 activity and other atherosclerosis markers in patients with primary IO after iron depletion.Materials and Methods:The study initially included 20 male patients with primary IO, defined by liver histology,from which 7 were lost during follow-up and 13 completed the study (mean follow-up duration: 24±6 months).Phlebotomy treatment consisted in the removal of 1 unit of blood weekly or biweekly. We recorded traditional cardiovascular risk factors, high sensitivity C-reactive protein (hsCRP), and Lp-PLA2 activity. Longitudinal differences were tested by paired T or Wilcoxon tests. Linear regression was used to evaluate the relationship between changes in ferritin and in Lp-PLA2.Results: HFE mutations were present in 77% of the patients. Besides ferritin concentration (-74%), ALT (-11%) and Lp-PLA2 activities (-14%) were reduced after iron depletion (all p<0.05). Linear regression showed that changes in ferritin levels explained a 60% of the variability in the changes of Lp-PLA2 activity (B=0.80, p=0.008, R2 = 0.60).Conclusions: Treatment by phlebotomy significantly reduced the levels of Lp-PLA2 activity besides its expected effects in liver markers. The implications of iron depletion for the reduction of CVD risk remain to be studied.Fil: Tetzlaff, Walter Francisco. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Martín, Maximiliano Emmanuel. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; ArgentinaFil: Botta, Eliana Elizabeth. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Saez, María Soledad. Hospital Italiano; ArgentinaFil: Ferraro, Maria Florencia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Boero, Laura Estela. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; ArgentinaFil: Sorroche, Patricia B. Hospital Italiano; ArgentinaFil: Arbelbide, Jorge. Hospital Italiano; ArgentinaFil: Brites, Fernando Daniel. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Meroño, Tomás. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentin
